Sanofi-Aventis:Sanofi Pasteur To Enter Japan With Pediatric Vaccine
Monday November 10th, 2008 / 8h21
Edited Press Release PARIS -(Dow Jones)- Sanofi Pasteur, the vaccines division of Sanofi-Aventis (SNY), announced Monday that it is the first international vaccine company to enter the Japanese pediatric vaccine market with ActHIB vaccine (Haemophilus influenzae type b conjugate vaccine). Sanofi Pasteur's ActHIB vaccine is marketed in Japan by Daiichi-Sankyo Co., Ltd. (4568.TO), and will be available starting Dec. 19. The World Health Organization estimates that Hib is responsible for three million serious illnesses and an estimated 400 000 deaths per year worldwide, mainly caused by meningitis and pneumonia. Almost all victims are children under the age of five, those between four and 18 months of age being especially vulnerable. Every year in Japan, about 500 children are affected by this devastating disease, of whom approximately 25 die and 100 suffer from serious sequelae. Company Web site: www.sanofipasteur.com Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http://www.djnewsplus.com/al?rnd=IDbR9DERIRN9iLRqXQUEig%3D%3D. You can use this link on the day this article is published and the following day.
Sanofi-Aventis est le 1er groupe pharmaceutique europ éen. Le CA par famille de produits se répartit comme suit :
- produits pharmaceutiques (89,6%)...
